The AI-Ready Investor: How VCs Can Use AI to Find the Next Breakthrough in Life Sciences According to Leen Kawas

The biotechnology investment landscape has fundamentally changed. Traditional drug discovery timelines that stretch 8-10 years from target identification to human trials are being compressed by artificial intelligence applications that can analyze massive datasets in days rather than decades.

Leen Kawas, Managing General Partner at Propel Bio Partners, has witnessed this transformation from multiple angles. As a biotech CEO, she saw firsthand how AI could accelerate drug development. Now, as an investor, she’s actively funding the next generation of AI-driven life sciences companies.

“We see a big surge in the number of companies that are trying to use AI and predictive modeling to accelerate drug development and discovery,” Leen Kawas observed in early 2023. For venture capitalists, this surge represents both unprecedented opportunity and new evaluation challenges. The question isn’t whether AI will transform life sciences—it’s how investors can identify which AI applications will deliver breakthrough results.

Read the Full Article Here